{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-016867","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.734916+00:00","generated_at":"2026-05-21T08:01:30.411859+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dyadic Q1 2025 revenue $394K, net loss $2.028M; cash $7.3M; progress on C1 platform grants","bullets":["Revenue $394K, up from $335K YoY, driven by $210K in Gates Foundation and CEPI grant revenue.","Net loss $2.028M vs $2.01M YoY; operating loss improved to $2.002M from $2.126M.","Cash, cash equivalents and securities $7.3M at March 31, 2025, down from $9.3M at Dec 31, 2024.","Up to $4.5M CEPI grant and $3M Gates Foundation grant advancing C1 platform for vaccines and antibodies.","Commercial launch of recombinant Human Serum Albumin expected Q3 2025; dairy enzyme launch late 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-016867","json":"https://secwatch.observer/filing/0001437749-25-016867.json","markdown":"https://secwatch.observer/filing/0001437749-25-016867.md","text":"https://secwatch.observer/filing/0001437749-25-016867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774925016867/0001437749-25-016867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774925016867/dyai20250107_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:01:30.411859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}